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ABSTRACT
Objective: The objective of this research was to evaluate of warfarin oral used by value and determination frequency of international normalized 
ratio (INR).
Methods: The data of cardiovascular patients were collected from medical records in Haji Adam Malik General Hospital, Medan, North Sumatera, 
Indonesia, in 2016. This study evaluated the data by retrospective study design. The sample study was selected by Slovin method from the population 
of medical record of cardiovascular patients who received warfarin therapy. The sample of population was divided based on how many times the INR 
was measured. The groups are no measurement, once a year, unregularly schedule, thrice a year, and every month. The data were analyzed by analysis 
of variant to evaluated association of INR values and groups of patients.
Result: The total sample in this study was 90 patients based on Slovin formula. The percentage of patient who never gets INR checked was 18.89%, 
once a year was 32.2%, unregularly was 34.44%, thrice a year was 8.89%, and every month was 5.56%. The value of INR in groups was 0.00 ± 0.00 in 
never checked group, once in year was 1.18 ± 0.44, unregularly was 1.79 ± 1.00, once time in 3 months was 2.04 ± 0.73, and every month was 2.42 ± 
0.91. The groups of patients with never evaluation of INR value were significantly different with the other groups (p≤0.05).
Conclusion: The results obtained in this study indicated the majority patients group in case of warfarin oral used and evaluation of bleeding status 
were once checked in year and unregularly determination of INR value. The best condition, in this case, was the determination of INR value in every 
month caused the bleeding or coagulation status of patient can be evaluated.
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INTRODUCTION
The bleeding is the common problem in cardiovascular disease. The two 
types of bleeding in cardiovascular are ischemic and hemorrhage. The 
bleeding event was caused by a disorder or manipulating (mechanic or 
pharmacologic) in the treatment of the disease [1]. The pharmacologic 
manipulation associated with clinically significant side effects from 
medicines and supplements [2,3].
The bleeding is related to the anticoagulant grouped by minor and 
major bleeding. The minor bleeding such as in the nose, pharynx, 
urinary tract, soft tissue, and joint space. The major bleeding such 
as in cerebrovascular (intracranial) and gastrointestinal (40–60%) 
systems that may occur in the retroperitoneal region and intraocular. 
Intracranial hemorrhage is a fatal hemorrhage associated with warfarin 
therapy. Although the incidence is estimated to range from 0.3% to 2%, 
60% of sufferers experience death from the incidence value [4].
Heparin is a parenteral anticoagulant that acts as indirect thrombin 
inhibitor and is extensively used for treatment and prophylaxis of 
several thromboembolic conditions in clinical practice. Heparin is a 
heterogeneous mixture of sulfated mucopolysaccharides whose biologic 
activity is dependent on the endogenous anticoagulant antithrombin. 
Commonly use oral anticoagulant is warfarin [5].
The 50% of the bleeding that occurs is major bleeding. The bleeding 
associated with warfarin causes morbidity due to transfusion and 
hospitalization. An average of 1 in 10 major hemorrhages causes death 
and 1 in 12 patients will experience bleeding after reuse of warfarin [6]. 
During the development of research on major bleeding related to warfarin, 
the mortality rate reached 9.5–13.4% [7,8]. An examination of the 
international normalized ratio (INR) in patients receiving warfarin 
therapy is needed to monitor the chances of bleeding [9,10].
Based on high mortality rate due to bleeding because of warfarin usage, 
evaluation of warfarin based on INR value and relation with bleeding 
number of patient needs to be evaluated. In this study, patients of 
cardiovascular disease who received warfarin were grouped by 
frequency of the determination of INR values.
METHODS
Ethical clearance
The study was approved by Health Research Ethical Committee, 
Medical Faculty of University of Sumatera Utara/Haji Adam Malik 
General Hospital with an ethical clearance number of 368/TGL/KEPK 
FK USU-RSUP HAM/2017.
Study design
The study design in this research was case–control study. The data were 
collected by retrospective method for evaluation of clinical condition 
and identify study participants based on their case status in medical 
record. This study was compared and analyzing statistical associations 
between exposure and outcomes [11].
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i4.23600
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Time and location
This study was conducted at Haji Adam Malik Hospital from May to 
September 2017, and the data used in study were taken from 2016s data.
Population and sample
The population was all of the cardiovascular patients’ medical record in 
Haji Adam Malik Hospital, Medan, Indonesia. The sample was collected 
by simple random sampling method from the medical record in 
2016 year period. The simple random sampling method used the Slovin 





n: The number of sample, N: The number of population, e: The number 
of deviation or error (10%).
The collected sample was grouped by the type of determination 
frequency of INR value; there are no measurements, once in year 
period, unregularly, thrice a year, and every month.
Statistical analysis
Statistical analysis was conducted using analysis of variant method to 
identify significantly different between all groups and conclude the 
relationship of determination frequency of INR value and warfarin used. 
In this study, the independent variable was determination frequency 
and dependent variable was INR value for the evaluation of coagulant 
or bleeding status in patients.
RESULT
Characteristic of patients demography
The number of patients by sex can be viewed in Table 1.
Based on the data obtained, it is known that the number of male patients 
is greater than female patients. Warfarin usually prescribed because 
both male and female patients are equally at risk for blood coagulation.
The number of patients by age can be viewed in Table 2.
Based on the data, patients with the most coagulation are patients over 
the age of 60 years, followed by patients between 50 and 60 years. 
The older the human age the ability of the organs of the body to work 
decreases. In this case, blood clotting factors with age also decrease in 
function so it is more susceptible to coagulation. Patients in this age 
range should be more supervised during warfarin prescribing because 
age is a risk factor for heart disease.
The INR value by the group of determination frequency can be viewed 
in Table 3.
Based on the data, it can be concluded that the INR checks performed 
every 1 month are the most appropriate frequency. From statistical 
data, checks every 3 months and 1 month can be evaluated, but for 
examination, every 3 months does not differ significantly with irregular 
examination, so the examination every 1 month is the best result. 
The 0.00 value in the never measured group is not the true value but 
indicates that the value is unknowable.
DISCUSSION
Based on medical record, the number of patients who do not regularly 
performs the INR (laboratory), one of which is due to patient 
disobedience to the therapy procedure. The patient’s educational, 
economic, social, and psychological affects him immensely. Non-
compliance increases mortality, morbidity, and hospitalization. 
Compliance is the patient’s own responsibility to follow a medical 
therapy program. Compliance is a multidimensional phenomenon that 
interacts among many factors [12,13].
INR monitoring in patients with low thrombotic risk is done daily until 
INR 2–3 is reached if it is stable enough to examine 4–6 weeks. While for 
patients with high thrombotic risk, an initial examination is done every 
3 days until the INR value reaches 2, then every week to INR 2–3, if the INR 
has stabilized then it should be checked once every 4–6 weeks [14-16].
Evidence suggests that stroke prevention by warfarin is effective 
when the time in therapeutic range (TTR) is either >70%. TTR is the 
proportion of time when INR 2–3 is achieved compared to overall 
duration of warfarin consumption. Therefore, continuous dose 
regulatory efforts should be made to obtain target values of INR 2–3. 
The difficulty of using warfarin in Indonesia is the unavailability of the 
INR inspection facility in peripheral areas. In this regard, it should also 
be noted that genetic factors in Indonesian ethnicity are related to the 
sensitivity of individuals to warfarin [17].
CONCLUSION
The examination of INR values is an important factor in the evaluation 
of coagulation and bleeding events in the treatment of cardiovascular 
disease using anticoagulant therapy such as warfarin with periodic 
checks; health workers can monitor the use of drug doses to achieve a 
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